I have been practicing internal medicine for over a decade. In that time, I have watched the treatment landscape for obesity and metabolic disease evolve slowly — and then, with the emergence of GLP-1 receptor agonists, very quickly.

The conversation around these medications has become, in many ways, impossible to have calmly. On one side: breathless enthusiasm, celebrity endorsements, and a market that has outpaced supply. On the other: skepticism, concern about misuse, and legitimate questions about long-term safety in populations that have not yet been studied.

What I want to offer here is neither enthusiasm nor skepticism. I want to offer the evidence — what it shows, what it does not show, and what it means for patients who are considering GLP-1 therapy as part of a medically supervised program.

GLP-1 therapy is not a shortcut. It is a clinical tool — and like all tools, its value depends entirely on how it is used.

What GLP-1 Receptor Agonists Actually Do

GLP-1 — glucagon-like peptide-1 — is a hormone produced naturally in the gut in response to food. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. GLP-1 receptor agonists mimic this hormone, amplifying and extending its effects.

The result, in clinical practice, is a meaningful reduction in appetite and food intake, improved glycemic control, and — in the landmark trials — significant and sustained weight loss. The SURMOUNT-1 trial of tirzepatide showed a mean weight reduction of 22.5% at 72 weeks in non-diabetic adults with obesity. The STEP trials of semaglutide showed comparable results. These are not modest effects. They are clinically significant.

What the Research Does Not Yet Show

The long-term data — beyond two to three years — is still limited. We do not yet have robust evidence on what happens to patients who discontinue therapy after extended use, or on the effects of these medications in populations that were underrepresented in the trials, including certain ethnic groups and patients with complex comorbidities.

The concern about muscle mass loss is real and worth addressing directly. Studies have shown that a meaningful proportion of weight lost on GLP-1 therapy is lean mass rather than fat mass — a ratio that is less favorable than what is achieved through diet and exercise alone. This is why resistance training and adequate protein intake are not optional additions to a GLP-1 program. They are clinical requirements.

Who Is a Candidate — and Who Is Not

GLP-1 therapy is appropriate for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. It is not a treatment for patients who want to lose 10 pounds for an event.

Contraindications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, a history of pancreatitis, and certain gastrointestinal conditions. A thorough medical history and baseline labs are not optional — they are the foundation of safe prescribing.

What Physician Oversight Actually Means

The proliferation of telehealth GLP-1 prescribing has created a category of patients who are receiving these medications without adequate monitoring. No baseline labs. No follow-up appointments. No guidance on nutrition or exercise. No management of side effects.

At The Skin Parlor™, GLP-1 therapy is managed by Samuel Olaleye, MD — double board-certified in Internal Medicine and Obesity Medicine. Every patient begins with a comprehensive evaluation. Labs are reviewed. A protocol is built. Follow-up is scheduled. Side effects are managed. The medication is one component of a program, not the program itself.

This is what physician oversight means. Not a prescription sent to a pharmacy. A relationship between a patient and a clinician who is accountable for the outcome.